Skip to content

ACC/AHA 2025: acute coronary syndromes

International ACC/AHA Current

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes

Rao SV, et al. Circulation. 2025;151:e771–e862
DOI 10.1161/CIR.0000000000001309 · Summary checked against the source: 2026-11

Read or download the original

The first ACC/AHA guideline to cover STEMI and NSTE-ACS together; it replaces the 2013 STEMI and 2014 NSTE-ACS guidelines.

At a glance

  1. ECG within 10 minutes of first medical contact; repeat if non-diagnostic. High-sensitivity troponin, repeated at 1–2 hours (3–6 h for conventional assays). [1, B-NR · e783]
  2. Primary PCI within 90 minutes of first medical contact (≤120 min if transferred) for STEMI <12 h. [1, A · e803]
  3. Fibrinolysis if PCI will take >120 minutes (onset <12 h), door-to-needle ≤30 min, then transfer for angiography in 2–24 h (rescue PCI at once if it fails). [1, A · e804; 1, B-R · e806]
  4. Aspirin + a P2Y12 inhibitor: prasugrel or ticagrelor with PCI; clopidogrel with fibrinolysis. DAPT for ≥12 months unless bleeding risk is high. [1, A · e789, e826]
  5. High-intensity statin; add non-statin therapy if LDL ≥70 mg/dL (reasonable at 55–69). [1, A; 2a, B-R · e797]
  6. Radial access; intracoronary imaging for left main or complex PCI; complete revascularisation of non-culprit lesions in stable patients, but not during cardiogenic shock. [e810–e815]
  7. Cardiac rehabilitation referral before discharge; annual influenza vaccine. [1, A · e824, e832]

Initial assessment

Class 1 [e780–e783]

  • 12-lead ECG within 10 minutes of first medical contact; serial ECGs if the first isn't diagnostic. [1, B-NR · e780]
  • Suspected STEMI: EMS straight to a PCI-capable hospital, with pre-arrival cath-lab activation. [1, B-NR · e780]
  • Troponin as soon as possible, ideally high-sensitivity; repeat at 1–2 h (hs-cTn) or 3–6 h (conventional). [1, B-NR · e783]

Oxygen and cardiac arrest [e786–e787]

  • Oxygen only if SpO₂ <90%; routine oxygen gives no benefit. [1, C-LD · e787]
  • Resuscitated cardiac arrest with STEMI: primary PCI (if not comatose, or comatose with a favourable prognosis). [1, B-NR · e786]

Antithrombotic therapy

Drug Loading Maintenance
Aspirin 162–325 mg chewed (even if already taking it) 75–100 mg daily
Clopidogrel, no fibrinolysis 300 or 600 mg 75 mg daily
Clopidogrel with fibrinolysis 300 mg if ≤75 years; 75 mg if >75 75 mg daily
Prasugrel (PCI only) 60 mg 10 mg daily; 5 mg if <60 kg or ≥75 years
Ticagrelor 180 mg 90 mg twice daily

Adapted from ACC/AHA 2025 Table 7 [e789]

P2Y12 choice [e789]

  • NSTE-ACS with PCI: prasugrel or ticagrelor; managed without invasive evaluation: ticagrelor. [1, B-R]
  • STEMI with primary PCI: prasugrel or ticagrelor. [1, B-R]
  • STEMI with fibrinolysis: clopidogrel. [1, A]
  • Clopidogrel when prasugrel or ticagrelor can't be used. [1, B-R / C-LD]

Class 3: Harm

  • Prasugrel after previous stroke or TIA. [3: Harm, B-R · e789]
  • Routine glycoprotein IIb/IIIa inhibitors (keep them for large thrombus, no-reflow or slow flow). [3: Harm, B-R · e793]
  • Fondaparinux alone to support PCI (catheter thrombosis). [3: Harm, B-R · e794]
Anticoagulant Use and dose
UFH NSTE-ACS and PCI: 60 IU/kg bolus (max 4000), 12 IU/kg/h (max 1000), aPTT 60–80 s; PCI target ACT 250–300 s (Class 1)
Enoxaparin 1 mg/kg SC 12-hourly (daily if CrCl <30). Alternative in NSTE-ACS when early invasive isn't planned (1, B-R); preferred with fibrinolysis if no invasive plan (1, A)
Fondaparinux Alternative in conservatively managed NSTE-ACS or after fibrinolysis; not alone for PCI
Bivalirudin Alternative to UFH in STEMI PCI (1, B-R); 0.75 mg/kg bolus then 1.75 mg/kg/h

Continue parenteral anticoagulation until revascularisation, or after fibrinolysis for up to 8 days. Adapted from ACC/AHA 2025 Table 10 and recommendations [e794–e795]

STEMI reperfusion

flowchart TD
    A["Symptoms suggesting ACS"] --> E["Call EMS (preferred):<br/>prehospital ECG within 10 min, suspect STEMI"]
    A --> S["Own transport"]
    E --> T["Direct to PCI centre, activate cath lab from the field"]
    T --> P1["Goal: FMC-to-device ≤90 min → primary PCI"]
    S --> NP["Arrives at non-PCI centre:<br/>door-to-ECG ≤10 min, diagnose STEMI"]
    S --> PC["Arrives at PCI centre:<br/>door-to-ECG ≤10 min, activate cath lab"]
    PC --> P2["FMC-to-device ≤90 min (direct)<br/>→ primary PCI"]
    NP --> D{"Primary PCI feasible within<br/>120 min of FMC?"}
    D -->|"Yes, or lysis contraindicated"| TR["Urgent transfer, straight to cath lab<br/>FMC-to-device ≤120 min → primary PCI"]
    D -->|No| F["Fibrinolysis: door-to-needle ≤30 min"]
    F --> F2["Transfer to PCI centre immediately<br/>Failed or unstable: rescue PCI now<br/>Successful and stable: angiography in 2–24 h"]
Adapted from ACC/AHA 2025 Figure 6 [e802]

Timing Recommendation Grade
<12 h Primary PCI, FMC-to-device ≤90 min (≤120 min with transfer) 1, A
12–24 h Primary PCI is reasonable 2a, B-NR
>24 h with ongoing ischaemia or life-threatening arrhythmia Primary PCI is reasonable 2a, C-LD
>24 h, stable, occluded artery PCI gives no benefit 3: No benefit, B-R
Cardiogenic shock Emergency revascularisation of the culprit, whatever the time 1, B-R
ST depression only (not posterior MI) No fibrinolysis 3: Harm, B-R

Adapted from ACC/AHA 2025 [e803–e805]

Fibrinolysis

Agent Dose
Tenecteplase Single weight-based bolus: 30 mg <60 kg, 35 mg 60–69, 40 mg 70–79, 45 mg 80–89, 50 mg ≥90 kg
Reteplase Two 10-unit boluses 30 min apart
Alteplase 90-min infusion: 15 mg bolus, then 0.75 mg/kg over 30 min (max 50), then 0.5 mg/kg over 60 min (max 35)

Adapted from ACC/AHA 2025 Table 13 [e806]

Absolute contraindications Relative contraindications
Any previous ICH Chronic severe poorly controlled hypertension
Structural cerebrovascular lesion (AVM) SBP >180 or DBP >110 on presentation
Malignant intracranial tumour Ischaemic stroke >3 months ago; dementia
Ischaemic stroke within 3 months (except acute stroke within 4.5 h) Traumatic or prolonged (>10 min) CPR
Suspected aortic dissection Major surgery within 3 weeks; internal bleeding within 2–4 weeks
Active bleeding or bleeding diathesis (not menses) Non-compressible vascular puncture
Significant head or facial trauma within 3 months Pregnancy; active peptic ulcer
Intracranial or spinal surgery within 2 months Oral anticoagulant therapy
Severe uncontrolled hypertension (SBP >180 or DBP >110, unresponsive)

Adapted from ACC/AHA 2025 Table 14 [e806]

NSTE-ACS: invasive strategy

Risk Strategy Grade
Refractory angina, haemodynamic or electrical instability Immediate invasive 1, C-LD
High risk Early invasive within 24 h 2a, B-R
Intermediate or high risk, revascularisation candidate Invasive approach during the admission 1, A
Not high risk, invasive planned Angiography before discharge 2a, B-R
Low risk Routine invasive or selective invasive 1, A

Adapted from ACC/AHA 2025 [e807]

Revascularisation details

  • Radial over femoral access. [1, A · e810]
  • IVUS or OCT guidance for left main or complex lesions. [1, A · e811]
  • STEMI with multivessel disease, stable: PCI of significant non-culprit lesions (at the index procedure or staged). [1, A · e812]
  • Cardiogenic shock: culprit-only PCI; routine non-culprit PCI is harmful. [3: Harm, B-R · e815]
  • Microaxial flow pump (Impella) is reasonable in selected STEMI shock; routine IABP gives no benefit. [2a, B-R; 3: No benefit · e816]

Secondary prevention

Therapy Recommendation Grade
Beta-blocker Oral, within 24 h, if no contraindication 1, A
ACEi or ARB LVEF ≤40%, hypertension, diabetes or anterior STEMI 1, A
Other patients: reasonable 2a, A
MRA LVEF ≤40% with heart failure or diabetes 1, B-R
High-intensity statin All 1, A
Add non-statin (ezetimibe, PCSK9 inhibitor) LDL ≥70 mg/dL on maximal statin 1, A
LDL 55–69 mg/dL 2a, B-R
Start ezetimibe with the statin 2b, B-R
Lipid panel 4–8 weeks after starting or changing therapy 1, C-LD
Colchicine low dose May be reasonable 2b, B-R
ICD LVEF ≤40% (see criteria) ≥40 days after MI and ≥90 days after revascularisation 1, A
Cardiac rehabilitation Refer before discharge 1, A
Influenza vaccine Yearly 1, A
Transfusion Hb ≥10 g/dL may be reasonable in anaemia 2b, B-R

Adapted from ACC/AHA 2025 [e797–e832]

DAPT after discharge

  • DAPT for at least 12 months if not at high bleeding risk. [1, A · e826]
  • Ticagrelor monotherapy after ≥1 month of tolerated DAPT, to reduce bleeding. [1, A · e826]
  • PPI with DAPT or anticoagulants if GI bleeding risk is high. [1, A · e826]
  • De-escalation to clopidogrel, or single antiplatelet after 1 month in high bleeding risk: may be reasonable. [2b, B-R · e826]
  • Needs an oral anticoagulant: stop aspirin after 1–4 weeks of triple therapy; continue OAC + P2Y12 inhibitor (clopidogrel preferred). [1, B-R · e829]

Clinical pearls

  • Door-to-ECG 10 min; FMC-to-device 90 min (120 with transfer); door-to-needle 30 min.
  • Fibrinolysis → angiography in 2–24 h; rescue PCI for failed reperfusion.
  • No prasugrel after stroke or TIA; reduce to 5 mg if <60 kg or ≥75 years.
  • Shock: culprit-only PCI; no routine IABP.
  • LDL goal now <70, ideally <55 mg/dL after ACS.

Classes and levels of evidence

How ACC/AHA 2025 grades its recommendations. Adapted from ACC/AHA 2025 Table 2 [e778]. Hover over any class or level cited on this page to see what it means.

Class Strength Meaning Wording used
Class 1 Strong Benefit >>> risk is recommended; is indicated, useful, effective or beneficial; should be performed or administered
Class 2a Moderate Benefit >> risk is reasonable; can be useful, effective or beneficial
Class 2b Weak Benefit ≥ risk may or might be reasonable; may or might be considered; usefulness is unknown, unclear or uncertain
Class 3: No benefit Moderate Benefit = risk (generally used only with level A or B) is not recommended; is not indicated, useful or effective; should not be performed or administered
Class 3: Harm Strong Risk > benefit potentially harmful; causes harm; associated with excess morbidity or mortality; should not be performed or administered
Level Meaning
Level A High-quality evidence from more than one RCT, meta-analyses of high-quality RCTs, or one or more RCTs corroborated by high-quality registry studies
Level B-R (randomised) Moderate-quality evidence from one or more RCTs, or meta-analyses of moderate-quality RCTs
Level B-NR (non-randomised) Moderate-quality evidence from one or more well-designed, well-executed non-randomised, observational or registry studies, or meta-analyses of such studies
Level C-LD (limited data) Randomised or non-randomised observational or registry studies with limitations of design or execution, meta-analyses of such studies, or physiological or mechanistic studies in humans
Level C-EO (expert opinion) Consensus of expert opinion based on clinical experience

Class (strength) and level (quality) are judged independently, so any class can pair with any level. A level C recommendation isn't necessarily weak: many important clinical questions can't be tested in trials, yet there may be clear clinical consensus.